Most patients with acute myeloid leukemia (AML) and t(8;21) or inv(16) have a good prognosis with current anthracycline-and cytarabine-based protocols. Tandem analysis with flow cytometry (FC) and real-time RT-PCR (RQ-PCR) was applied to 55 patients, 28 harboring a t(8;21) and 27 an inv(16), including one case with a novel CBFbeta/MYH11 transcript. A total of 31% (n ¼ 17) of CR patients relapsed: seven with t(8;21) and 10 with inv(16). The mean amount of minimal residual disease (MRD) detected by FC in relapsed and nonrelapsed patients was markedly different: 0.3 vs 0.08% (P ¼ 0.002) at the end of treatment. The mean number of fusion transcript copies/ ABLx10 4 also differed between relapsed and non-relapsed patients: 2385 vs 122 (P ¼ 0.001) after induction, 56 vs 7.6 after intensification (P ¼ 0.0001) and 75 vs 3.3 (P ¼ 0.0001) at the end of chemotherapy. Relapses were more common in patients with FC MRD level 40.1% at the end of treatment than in patients with p0.1%: cumulative incidence of relapse (CIR) was 67 and 21% (P ¼ 0.03), respectively. Likewise, using RQ-PCR, a cutoff level of 410 copies at the end of treatment correlated with a high risk of relapse: CIR was 75% for patients with RQ-PCR 410 compared to 21% for patients with RQ-PCR levels p10 (P ¼ 0.04). Combined use of FC and RQ-PCR may improve MRD detection, and provide useful clinical information on relapse kinetics in AML patients.
Introduction
Acute myeloid leukemia (AML) with t(8;21) and inv (16) accounts for about 15% of adult AML. Based on results from large clinical studies, both leukemia types are included in the same good prognosis category. 1 Most patients achieve a complete remission (CR) after standard induction chemotherapy, and long-term remission rates of 60-70% have been reported after consolidation therapies with cytarabine or autologous transplant. Despite these encouraging results, 20-30% of patients relapse. To identify this subgroup of patients, several risk factors have been introduced in recent years. [2] [3] [4] [5] CD56 expression for the t(8;21) patients, leukocyte counts or white blood cell index for both types of core binding factor (CBF) leukemias have been purported as suggestive of a poor outcome. Leukemic cells present in the bone marrow of patients with AML in the CR phase are thought to be responsible for the emergence of the relapses. Monitoring MRD by molecular or immunophenotypic methods seem to be of interest to define those patients with a high risk of relapse. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Molecular techniques based on the detection of gene-fusion products are restricted to AML with specific chromosomal rearrangements, whereas multiparametric flow cytometry (FC) may be applied to more than 80% of AML cases. Accordingly, MRD in AML with t(8;21) and inv(16) AML may be analyzed using both methods. In the present study, we found that MRD detection by FC and/or by real time RT-PCR (RQ-PCR) during the follow-up of these patients allowed us to identify patients with a high risk of relapse.
Methods

Patients
In all, 65 patients with core binding factor (CBF) leukemias, 30 t(8;21)(q22;q22) and 35 inv(16)(p13q22)/t(16;16)(p13;q22), were included in the study. In all cases, diagnosis was established by conventional cytogenetics and/or a qualitative PCR assay (AML1/ETO or CBFbeta/MYH11 detection). 19 Patients' characteristics are reported in Table 1 . Most patients (83%, n ¼ 54) were adults aged p60 years with de novo AML and enrolled in a CETLAM (Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias agudas y Mielodisplasias) LMA-99 protocol. The remaining patients were five adults with de novo AML enrolled in a previous protocol from the CETLAM group (LMA-94), 20 three patients with a secondary AML, and three children (two cases with de novo AML and one case with a secondary AML). Immunophenotyping and PCR (qualitative and quantitative) analysis from bone marrow at diagnosis and in the follow-up phase were performed at the Hospital de la Santa Creu i Sant Pau (HSCSP) lab in Barcelona. Conventional karyotype was established using standard methods. The definition of a cytogenetic clone and descriptions of karyotypes followed the International System of Human Cytogenetic Nomenclature. 21 The FLT3 internal tandem duplication (FLT3-ITD þ ), point mutations in the tyrosine kinase domain of FLT3 (D835), and MLL rearrangements were also centrally analyzed at the HSCSP in Barcelona following well-established protocols. 22, 23 The white blood cell count (WBC), FAB diagnosis, clinical and outcome data were collected for each patient.
Treatment strategy
Patients included in the LMA-99 protocol were uniformly treated in accordance with the following schedule: one or two (if CR was not achieved with one chemotherapy course) cycles of induction therapy with IDICE (idarubicin, 12 mg/m 2 days 1, 3 and 5; etoposide, 100 mg/m 2 days 1, 2 and 3 and cytarabine, 500 mg/m 2 /12 h days 1, 3, 5 and 7). Patients who achieved a morphologic CR received one course of intensification treatment consisting of cytarabine (500 mg/m 2 /12 h days 1-6) and mitoxantrone (12 mg/m 2 days 4-6). Patients in CR were then allocated to different risk groups according to their karyotype and the number of induction therapy courses required to achieve CR. The good prognosis group included patients with inv(16) or t(8;21). These patients were treated with high-dose cytarabine (HDAC; 3 g/m 2 /12 h days 1, 3 and 5) and were not considered for transplant in first CR.
Patients enrolled in the LMA-94 protocol received one or two courses of induction therapy with ICE (idarubicin 10 mg/m 2 days 1, 3 and 5; cytarabine 100 mg/m 2 on continuous infusion days 1-7; etoposide 100 mg/m 2 days 1-3). Patients in CR received the same intensification treatment as that used in the LMA-99 protocol. Patients with inv(16)/t(8;21) were treated with HDAC.
Pediatric patients were treated according to SHOP-LANL-96 (n ¼ 1) and SHOP-LANL-2001 (n ¼ 2) protocols and all of them received an autologous stem cell transplant (auto-SCT) as intensification therapy.
Two out of three patients with secondary AML were treated according to the LMA-99 protocol and the remaining patient received an allogeneic stem cell transplantation with reduced intensity conditioning as first treatment.
Immunophenotypic analysis at diagnosis
The immunophenotype was performed on erythrocyte-lysed whole bone marrow (BM) samples obtained at diagnosis in 57 patients, 26 t(8;21) and 31 inv (16) . Antigenic expression of leukemic cells was systematically analyzed by multiparametric FC using triple stainings with the following fluorochromeconjugated (fluorescein isothiocyanate, FITC; phycoerythrin, PE; peridinin-chlorophyll protein, PerCp or phycoerythrin-cyanine 5, PE/Cy 5) combinations of monoclonal antibodies: CD15/ CD34/HLA-DR,CD10/CD20/CD19,CD2/CD33/CD19, CD22/ CD13/CD3, CD7/CD117/CD45, CD66/CD56/CD64,CD36/GA/ CD45,CD34/CD41/CD45,CD34/CD11b/CD45,CD4/CD123/ HLA-DR, CD14/CD135/CD45, CD5/CD16/CD45, MPO/CD79a/ CD3, TdT/MPO and lysozyme/lactoferrin/CD3. The acquisition and analyses were performed on a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA). At least 10 000 events/ tube were measured. Analytical gates were established according to CD45 reactivity and to FSC/SSC patterns. The PAINT-A-GATE PRO s software program (BDIS) was employed for subsequent data analysis.
MRD analysis by flow cytometry
The MRD study was performed in BM samples from patients in CR at different time points during and after therapy.
The strategy for MRD detection was based on detection of cells expressing an aberrant phenotype: asynchronous antigen expression, antigen overexpression and abnormal light scatter pattern. Monoclonal antibody combinations used in all cases were: CD15/CD34/HLA-DR, CD34/CD33/CD19, CD15/CD117/ CD45 and CD34/CD123/HLA-DR. These combinations included immature and myeloid markers commonly expressed in most AML cases. 24, 25 Table 2 summarizes the most frequent aberrant phenotypes identified at diagnosis. In inv(16) and t(8;21) AML, CD34 and CD123 positivity were found in all cases whereas CD117, CD33 and HLA-DR showed positivity in 92-96% of cases. These four combinations were also investigated in 14 BM samples obtained from healthy donors, and the percentage of the aberrant phenotypes was measured. Evaluation of cells displaying leukemia-associated phenotypes was performed using a two-step acquisition procedure according to previously defined methods. 6, 22 To assess the sensitivity of this Minimal residual disease in acute myeloid leukemia G Perea et al approach, we performed serial dilutional experiments of leukemic cells with normal BM cells. The detection limit ranged from one leukemic cell among 10 000 normal BM cells (10 À4 ) to one neoplastic cell among 100 000 normal cells (10 À5 ).
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Qualitative RT-PCR and RQ-PCR Mononucleated BM cells from patients were isolated using Lymphoprep s (Nycomed Pharma, Oslo, Norway). Total RNA was extracted with Trizol (Gibco BRL, Invitrogen, Carlsbad, CA, USA) and quantified by spectrophotometry, and input amount was optimized for retrotranscription. RT-PCR was performed on 1 mg of total RNA according to Biomed I recommendations. 19 Qualitative RT-PCR was routinely performed at diagnosis and during follow-up using the protocols designed by the European Biomed Group. 19 The ABL housekeeping gene was amplified as an internal control to check the RNA quality of each sample.
Quantitative CBFbeta/MYH11 (types A, D and E) and AML1/ ETO transcript levels were determined by RQ-PCR at diagnosis and in the follow-up according to methods developed by the European Concerted Action of the Europe Against Cancer Program 26 using the ABI PRISM 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA). The PCR reaction was carried out in a 25 ml reaction with 5 ml of cDNA, 12.5 ml (2 Â ) Taqman Universal PCR Master Mix (Applied Biosystems), 300 nM of primers and a 200 nM concentration of CBFbeta/ MYH11 and ABL probes. A 100 nM concentration was used for the AML1/ETO probe. The reaction conditions were 501C for 2 min and 951C for 10 min, followed by 50 cycles of 951C for 15 s and 601C for 1 min for annealing and extension. Both PCR reactions had a sensitivity of 10 À5 . All RQ-PCR experiments were performed in duplicate. The determination was repeated in cases with an outlying value. Standard curves for CBFbeta/ MYH11, AML1/ETO and ABL were obtained using a dilution series of plasmids (Ipsogen, Marseilles, France). Fusion transcript values obtained were normalized with respect to the number of ABL transcripts and expressed as fusion-gene copy number per 10 4 copies of ABL.
The estimated cutoff C t value of negativity was 40 for AML1/ ETO and 39 for CBFbeta/MYH11. These values were employed to establish the MRD sensitivity. Sensitivity level for each time point (induction, intensification and at the end of treatment) was assessed according to the method proposed by Biomed: SENS ¼ Àlog 10 (NCN, normalized copy number) Àlog 10 (CGCN, control gene copy number). 26 
Statistical analyses
CR and relapse were defined according to the criteria of the National Cancer Institute-sponsored workshop on AML. 27 Overall survival (OS) was measured from the date of enrollment until date of death and leukemia-free survival (LFS) for patients who achieved CR was measured from the date of CR to relapse or death. OS and LFS were plotted by the Kaplan-Meier method; differences between curves were analyzed by the log-rank test. The probability of relapse was calculated using cumulative incidence estimates and taking into account the competing risk. Univariate analyses of disease relapse were performed with univariate Cox models. For descriptive statistics, median, range and mean, or percentage of cases were calculated. Antigenic expression variability (positive vs negative) and other categorical variables were evaluated with Fisher's exact test. The MannWhitney U test was employed to compare continuous variables. A P-value o0.05 was considered significant.
Results
Follow-up and survival
The median follow-up for alive patients was 34 months (range: 5-108). Results of induction therapy were as follows: CR was obtained in 55 patients (84%); resistant disease was observed in three patients (5%) and seven patients (11%) died due to complications related to induction treatment.
Seven of 30 t(8;21) patients and 14 of 35 inv(16) patients died, resulting in an estimated OS after 2 years of 72 and 64%, respectively.
Of the 28 t(8;21) and 27 inv(16) patients achieving CR after induction therapy, seven and 10 patients relapsed, whereas three inv(16) patients died in first CR from treatment-related complications. In all, 21 t(8;21) and 14 inv(16) patients remained in continuous CR. The estimated LFS at 2 years was 73 and 50% in the t(8;21) and inv(16) groups, respectively. These differences between the two groups of patients were not statistically different.
Of 55 patients achieving CR after induction therapy, 53 received intensification treatment; one t(8;21) patient did not receive this treatment due to relapse and the other had a secondary inv(16) AML and underwent an allograft as a first treatment. In all, 52 of the 53 patients that received intensification completed the assigned treatment: HDAC (n ¼ 45), allo-SCT (n ¼ 2) and auto-SCT (n ¼ 5).
Molecular analysis
Qualitative RT-PCR was performed at diagnosis in 55 patients as follows: 25 cases with AML1/ETO and 30 with CBFbeta/MYH11 rearrangements. The transcript types identified in CBFbeta/ MYH11 patients were type A (n ¼ 26, 87%), type D (n ¼ 2, 7%), type E (n ¼ 1, 3%), and, in one case, a new in frame transcript (Figure 1 ). This new transcript (Z) seems to be the largest described until now. 28 RQ-PCR was performed at diagnosis in 50 patients: 22 t(8;21) and 28 inv (16) . The AML1/ETO/ABL transcript copy number Â 10 4 mean was 43710 (range: 15700-135000) and the CBFbeta/MYH11/ABL transcript copy number Â 10 4 was 14050 (range: 1400-58862). The mean value of the transcript number at diagnosis was higher for t(8;21) patients than for patients with inv(16) (P ¼ 0.006). Interestingly, the patient with the lowest CBFbeta/MYH11 transcript level corresponded to a previously reported masked inv (16) . 29 No significant differences were observed in the level of fusion gene transcript expression at presentation between patients who relapsed and those who remained in CR.
MRD assessment by FC
MRD was monitored in CR patients by FC in 173 follow-up samples obtained at different treatment time points: 40 after induction therapy, 30 after intensification therapy, 30 at the end of assigned chemotherapy treatment and 73 in subsequent controls. The mean amount of MRD detected was 1.15% (median: 0.8%, range: 0-6%) after induction, 0.2% (median: 0.05%; range: 0-1.2%) after intensification and 0.1% (median: 0.01%; range: 0-1%) at the end of treatment. No significant differences were found between relapsed and nonrelapsed patients in the mean amount of MRD detected, neither after induction (1 vs 1.5%) nor after intensification (0.18 vs 0.23%). The mean amount of MRD detected at the end of treatment in patients who relapsed was higher than for patients in continuous CR: 0.3 vs 0.08%, respectively (P ¼ 0.002). The mean MRD level after induction therapy was higher for t(8;21) patients than for those with inv(16): 1 vs 0.57% (P ¼ 0.002).
A cutoff level 41% after induction therapy and 40.1% after intensification and at the end of treatment correlated with a higher number of relapses (Table 3 ). MRD at the end of treatment was especially relevant because the CIR was 67% for patients with a level 40.1 and 21% for patients with a level p0.1% (P ¼ 0.03) (Figure 2 ). This was also true when t(8;21) and inv(16) patients were considered separately. The CIR according to MRD detected at the end of treatment for t(8;21) patients (n ¼ 16) was 67% when MRD was 40.1 and 15% when MRD was p0.1% (P ¼ 0.1), and for inv(16) patients (n ¼ 14) it was 67 and 28% (P ¼ 0.1), respectively. The MRD level identified after intensification was important for outcome in inv(16) patients: the OS was 100% for patients with MRD p0.1% (n ¼ 11) and 34% for patients with levels 40.1% (n ¼ 7) (P ¼ 0.02).
Patients with an MRD level 40.1% at any time between the completion of treatment and last follow-up had a higher risk of relapse than patients with MRD levels p0.1%; the CIR was 51 and 17%, respectively (P ¼ 0.06) ( Table 3 ). This was especially important for inv (16) patients: 80% of patients with value 40.1% relapsed vs 15% of patients with levels p0.1% (P ¼ 0.02). After induction, five out of 12 (CIR 58%) patients with more than 100 fusion transcript copies relapsed whereas five out of 19 (CIR 35%) with fewer than 100 fusion gene copies relapsed (P ¼ NS). After intensification, a threshold of 10 fusion gene copies was used and although patients with more than 10 copies relapsed more frequently than patients with fusion gene copies p10, differences did not attain statistical significance (Table 4) . Finally, at the end of treatment, three out of four patients with more than 10 fusion transcript copies relapsed, whereas only four out of 19 patients with p10 copies relapsed, resulting in an CIR of 75 and 21%, respectively (P ¼ 0.04) (Figure 3) .
The persistence of more than 10 chimeric gene transcript copies at the end of treatment was associated with a high risk of relapse both in t(8;21) (CIR was 50% for patients with 410 copies and 14% for those with p10 copies; P ¼ 0.2) and in inv(16) (CIR was 100 and 26%, respectively; P ¼ 0.06) patients.
Analysis of follow-up samples obtained from the end of chemotherapy until the last control revealed that patients who had 410 copies at any time during the follow-up had a significantly higher risk of relapse than patients who always had levels p10. The CIR at 2 years was 78% for patients with 410 copies and 13% for patients with p10 (P ¼ 0.002). This was relevant for inv (16) patients because all inv(16) patients with more than 10 copies at the end of treatment or in ensuing controls relapsed, whereas two of five t(8;21) patients with 410 (Ct ¼ 35.4) transcript copies analyzed following the BIOMED protocol were in CR after 1 and 4 years, respectively.
In tandem MRD analysis by FC and RQ-PCR
In 35 patients, 16 with t(8;21) and 19 with inv(16), MRD was assessed by FC and RQ-PCR at the same time point. A total of 74 samples were analyzed by both methods. The concordance rate was 67%: in 32 cases MRD was detected by both methods and in 18 samples MRD was ruled out by a negative result with the two tests. In five samples MRD was detected exclusively by FC and in 19 samples MRD relied exclusively on a positive RQ-PCR result (Table 5) . MRD was identifiable in a larger number of samples with the combined use of both techniques. Only two of 13 patients with less than 0.1% of MRD detected by FC and less than 10 fusion gene copies detected by RQ-PCR at the end of treatment relapsed; one patient had a type D CBFbeta/MYH11 transcript and the other presented a level 410 in the follow-up sample obtained 1 month later. The CIR at 2 years for patients with MRD p0.1% by FC and o10 fusion gene copies at the end of treatment was 14 and 63% for patients with MRD 40.1% by FC and/or 410 by RQ-PCR (P ¼ 0.03).
Discussion
Leukemic cells which remain undetected after chemotherapeutic treatments are responsible for relapse in AML patients. Multiparametric flow cytometry and molecular methods based on chimeric gene fusions are the preferred techniques in MRD studies. 6, 11, 12, [30] [31] [32] [33] Both methods have their limitations. FC may be applied to most AML cases and has the capacity to assess the status of nonleukemic compartments in the sample. Nevertheless, it requires a relatively large panel of monoclonal antibodies to detect the most common immunophenotypic aberrations, and also a certain degree of expertise. Sensitivity (i.e. the ability to detect a neoplastic cell in a mixed population of normal cells) is lower than for RT-PCR and it may consequently fail to detect a small residual tumor burden, leading to false-negative results. RT-PCR interpretation is easier and can detect one leukemic cell in 10 5 -10 6 normal cells. Realtime RT-PCR has been successfully applied to the follow-up of t(8;21) and inv(16) AML patients. 11, 12, 30, 33, 34 The presence of MRD has been associated with an increased risk of relapse in most clinical studies. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In our series we demonstrated that both FC and RQ-PCR may provide complementary information in the MRD follow-up of t (8, 21) and inv(16) AML patients. Previous studies using multiparametric FC have shown the prognostic value of MRD identification after AML treatment. FC has been proposed as a valuable tool to stratify the risk of relapse after induction and it has also been correlated with OS in some studies. [6] [7] [8] [9] [10] Data obtained from patients with CBF leukemias suggest that MRD levels after induction therapy failed to detect patients at high risk of relapse. Our results support earlier findings from studies suggesting the amount of MRD detected by FC at the end of the planned treatment is associated with a high risk of relapse. The cutoff level of 40.1% at this time point has also been proposed by other authors. 10 RQ-PCR can determine the amount of leukemic fusion transcripts arising from chromosome translocations. PCR evaluation of CR samples has been successful in other leukemia types. Molecular methods have been widely used to identify patients at risk in acute promyelocytic leukemia and acute lymphoblastic leukemia. [34] [35] [36] [37] RQ-PCR have not been routinely applied to detect AML1/ETO and CBFbeta/MYH11 fusion genes in large clinical protocols. BIOMED standardization efforts represent a major advance in implementing these techniques in clinical studies. 19, 26 Using conventional nested RT-PCR assays, most authors have found AML1/ETO transcripts in patients in CR, even many years after therapy has ended. 13, 16, 17, 33 These results may be explained in the light of our findings; AML1-ETO long survivors may harbor a relatively high number of copies (410 copies). In the case of inv (16) , standard nested RT-PCR studies have produced conflicting results: about 20-30% of PCR-negative patients eventually relapsed and few long-term survivors achieved PCR negativity. 11, 12, 30 Threshold levels that identify patients with a high risk of relapse have been reported by different authors for inv(16) and t(8;21) AML cases. 11, 12, 30, 38 We tried to define a threshold for each treatment point, but in early phases of CR we were unable to find differences between relapsed and nonrelapsed patients. In contrast, at the end of the planned treatment a cutoff of copy number 410 was found to be useful to discriminate between patients with high and low risk of relapse. These results are in agreement with previous data reported for inv (16) patients by other groups. 11, 12, 30 The clinical relevance of this value is emphasized by the fact that only three patients with fewer than 10 copies have relapsed. We found that most inv(16) patients who remained in continuous CR achieved a PCR level of 1 copy. Most importantly, they maintained this level for a long time whereas most relapsed patients did not achieve the threshold of 1 copy (only two relapsed patients reached this level). In contrast, we observed levels 410 copies in the followup of t(8;21) patients in continuous CR.
We found a strong concordance between the two MRD methods. Discordant cases may be of special interest as is exemplified by the inv(16) patient with a new transcript reported herein. CBFbeta/MYH11 rearrangements are heterogeneous and may escape conventional molecular methods. FC results are of special concern in this setting. The combination of two techniques and the future establishment of thresholds may facilitate the introduction of therapeutic changes based on MRD results. 37, 39 In our series, only two patients with values of less than 0.1% by FC and o10 copies at the end of treatment relapsed and both patients had an inv (16) . Strict follow-up was available in one of these two cases. In this patient, relapse was preceded by an increase in the tumor burden detected by FC and RQ-PCR.
In accordance with our results, it seems appropriate to investigate the MRD status at the end of the chemotherapy treatment. Future prospective studies should solve this issue.
In conclusion, MRD analysis represent a feasible strategy to stratify AML patients with favorable cytogenetics. Standardization and simplification of analytical methods will enhance their use in ongoing and future clinical trials. ).
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